Nanoparticle characterization in vivo

Establishing the safety and toxicity of new nanoparticles in animal models is an important step towards developing therapeutics for the clinic.  Today, I will talk federal recommendations on how to design preclinical studies and the role that these assay play within the path to FDA approval.

AnneAnne L van de Ven is an Associate Research Scientist at Northeastern University, where she combines high throughput nanoparticle synthesis with quantitative imaging and multiscale modeling to study and optimize cancer treatment in preclinical animal models. As Assistant Director of CaNCURE and Research Coordinator of the IGERT Nanomedicine program, she is highly involved in the education and training of future of nanomedicine leaders. Anne received her Ph.D. in Bioengineering from Rice University in 2008. From 2009 to 2013, she developed optical techniques for real-time monitoring nanoparticle-based drug delivery and treatment response under the supervision of Dr. Mauro Ferrari. Dr. van de Ven has 12 years experience in translational nanomedicine, clinical collaboration, and pre-clinical experimental design. Her areas of expertise include: intravital microscopy, optical instrumentation, nanoparticle design and characterization, drug delivery, and animal models of cancer.